TCR2 Therapeutics
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
You can watch TCRR and buy or sell other stocks, ETFs, and their options commission-free!About TCRR
TCR2 Therapeutics, Inc. is a clinical-stage cell therapy company, which engages in the development of biological drugs and engineering T-cells for cancer therapy. It is also involved in the research and collaboration with academic laboratories and industry partners in the field of T-cell immunology, cell therapy, gene editing, and process development.
CEOGarry E. Menzel, PhD, MBA
CEOGarry E. Menzel, PhD, MBA
Employees—
Employees—
HeadquartersCambridge, Massachusetts
HeadquartersCambridge, Massachusetts
Founded2015
Founded2015
Employees—
Employees—
TCRR Key Statistics
Market cap58.11M
Market cap58.11M
Price-Earnings ratio-0.35
Price-Earnings ratio-0.35
Dividend yield—
Dividend yield—
Average volume694.31K
Average volume694.31K
High today—
High today—
Low today—
Low today—
Open price—
Open price—
Volume0.00
Volume0.00
52 Week high$3.88
52 Week high$3.88
52 Week low$0.821
52 Week low$0.821
People also own
Based on the portfolios of people who own TCRR. This list is generated using Robinhood data, and it’s not a recommendation.